PL2598165T3 - Immunogenne kompozycje przeciwzapalne - Google Patents

Immunogenne kompozycje przeciwzapalne

Info

Publication number
PL2598165T3
PL2598165T3 PL11811677T PL11811677T PL2598165T3 PL 2598165 T3 PL2598165 T3 PL 2598165T3 PL 11811677 T PL11811677 T PL 11811677T PL 11811677 T PL11811677 T PL 11811677T PL 2598165 T3 PL2598165 T3 PL 2598165T3
Authority
PL
Poland
Prior art keywords
inflammatory compositions
immunogenic anti
immunogenic
inflammatory
compositions
Prior art date
Application number
PL11811677T
Other languages
English (en)
Inventor
Harold David Gunn
Salim Dhanji
Original Assignee
Qu Biologics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/843,296 external-priority patent/US8501198B2/en
Priority claimed from US13/019,208 external-priority patent/US9107864B2/en
Application filed by Qu Biologics Inc. filed Critical Qu Biologics Inc.
Publication of PL2598165T3 publication Critical patent/PL2598165T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11811677T 2010-07-26 2011-07-26 Immunogenne kompozycje przeciwzapalne PL2598165T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12/843,296 US8501198B2 (en) 2004-06-07 2010-07-26 Tissue targeted antigenic activation of the immune response to treat cancers
US41137110P 2010-11-08 2010-11-08
US13/019,208 US9107864B2 (en) 2004-06-07 2011-02-01 Tissue targeted antigenic activation of the immune response to treat cancers
US201161500836P 2011-06-24 2011-06-24
EP11811677.1A EP2598165B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions
PCT/CA2011/000851 WO2012012874A1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions

Publications (1)

Publication Number Publication Date
PL2598165T3 true PL2598165T3 (pl) 2018-02-28

Family

ID=45529307

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11811677T PL2598165T3 (pl) 2010-07-26 2011-07-26 Immunogenne kompozycje przeciwzapalne

Country Status (17)

Country Link
US (1) US10130692B2 (pl)
EP (3) EP3235506B1 (pl)
JP (5) JP5923501B2 (pl)
KR (2) KR102157718B1 (pl)
CN (2) CN103140238B (pl)
AU (3) AU2016238866B2 (pl)
CA (2) CA2804709A1 (pl)
DK (1) DK2598165T3 (pl)
ES (2) ES2971415T3 (pl)
IL (2) IL224048B (pl)
MX (1) MX345240B (pl)
MY (1) MY188328A (pl)
NZ (2) NZ606490A (pl)
PL (1) PL2598165T3 (pl)
RU (2) RU2581922C2 (pl)
SG (2) SG10201604175XA (pl)
WO (1) WO2012012874A1 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
PL2598165T3 (pl) 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10988516B2 (en) * 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014059313A1 (en) * 2012-10-12 2014-04-17 Lehigh University Thermally stable enzymes, compositions thereof and methods of using same
WO2014160266A1 (en) * 2013-03-14 2014-10-02 Coronado Biosciences, Inc. Treatment of type i diabetes mellitus using helminthic parasite preparations
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
CN106456740B (zh) * 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节
WO2016075687A2 (en) * 2014-11-10 2016-05-19 Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. Attenuated or inactivated pathogenic escherichia coli for treating urogenital cancer
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
EP3662917A1 (en) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN105176882B (zh) * 2015-10-17 2018-09-21 福清市默克兽医院 一种牛摩氏摩根菌性关节炎灭活疫苗及其制备方法
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
CN109414461A (zh) 2016-04-26 2019-03-01 曲生物制品公司 治疗性地触发靶组织中的先天性免疫应答
CN105797153A (zh) * 2016-05-02 2016-07-27 浙江农林大学 兽用疫苗免疫佐剂及其制备与应用方法
CN106011007A (zh) * 2016-06-06 2016-10-12 余国华 多联耐药菌免疫活性蛋白及其制备方法和用途
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US10596206B1 (en) * 2017-03-14 2020-03-24 Cornell University Probiotic compositions and methods of use
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2018217764A1 (en) * 2017-05-22 2018-11-29 Kansas State University Research Foundation Microbiome transplantation
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
EP3716949A4 (en) 2017-11-29 2022-05-18 UTI Limited Partnership METHODS OF TREATMENT OF AUTOIMMUNE DISEASES
CN111867619A (zh) 2018-01-03 2020-10-30 曲生物制品公司 过继性细胞治疗的先天寻靶
MX2021000069A (es) * 2018-07-03 2021-05-31 Artizan Biosciences Inc Composiciones y metodos para tratar la enfermedad intestinal inflamatoria.
CN114051413A (zh) * 2019-06-28 2022-02-15 河谷细胞有限公司 增强吞噬作用而不引起炎症的药物组合物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN116875516B (zh) * 2023-09-06 2023-12-08 上海上药信谊药厂有限公司 青春双歧杆菌ba-3及其在抗衰老、抗氧化和抗炎中的应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928565A (en) 1971-10-19 1975-12-23 Yuzuru Homma Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties
US4326452A (en) 1977-10-24 1982-04-27 Matsushita Electric Industrial Co., Ltd. Fluid diverting assembly
JPS5946493B2 (ja) 1978-03-31 1984-11-13 株式会社三和化学研究所 異種死菌体混合物を有効成分とする抗腫瘍剤
JPS56108716A (en) 1980-01-30 1981-08-28 Sanwa Kagaku Kenkyusho:Kk Antiviral agent containing different kind dead cell mixture as effective component
JPS5839624A (ja) 1981-09-02 1983-03-08 Meiji Seika Kaisha Ltd 抗腫瘍剤
JPS6012071A (ja) 1983-06-30 1985-01-22 東レ株式会社 抗腫瘍作用を有する体液処理剤
US4880626A (en) 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
FR2683529B1 (fr) 1991-11-12 1994-02-04 Bretagne Occidentale Universite Composes pharmaceutiques gem-diphosphonates analogues du cis-platine.
US5292513A (en) 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
GB9406301D0 (en) 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US6447777B1 (en) * 1996-03-29 2002-09-10 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
US6348586B1 (en) 1996-07-25 2002-02-19 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6028060A (en) 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
JP2002509888A (ja) 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
BR0115246A (pt) * 2000-11-01 2005-04-26 Univ California Peptìdeos imunomoduladores derivados de proteìnas de choque e seu uso
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
FR2822071B1 (fr) 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
JP2005515162A (ja) * 2001-07-02 2005-05-26 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）を用いた単回ワクチン接種
JP4859341B2 (ja) 2001-07-19 2012-01-25 昭 林 ヒト免疫療法
WO2003013558A1 (en) * 2001-07-30 2003-02-20 Claudio De Simone Treatment of radiation-induced diarrhea with probiotics
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
AU2002353366A1 (en) 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
JP2006502964A (ja) 2002-02-06 2006-01-26 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン 特定の器官または組織に対する全身性免疫応答の標的化のための方法および組成物
WO2003068812A2 (de) 2002-02-15 2003-08-21 Agelab Pharma Gmbh Immunmodulierendes peptid aus s. aureus enterotoxin b
RU2004135541A (ru) 2002-06-11 2005-10-10 ГлаксоСмитКлайн Байолоджикалз с.а. (BE) Иммуногенные композиции
JP4618970B2 (ja) 2002-08-02 2011-01-26 マルホ株式会社 肛門圧低下外用剤
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
US7179460B2 (en) * 2002-12-05 2007-02-20 Danisco A/S Bacterial composition and its use
NZ569331A (en) * 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
AR043692A1 (es) 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
CA2522957C (en) * 2003-04-23 2013-10-22 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
CN1332018C (zh) * 2003-11-03 2007-08-15 安徽龙科马生物制药有限责任公司 冻干母牛分枝杆菌制剂（微卡）及其制备方法和用途
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
EP1684803B1 (en) * 2003-11-14 2010-07-07 UCL Business PLC Immune modulator comprising whole cell tsukamurella bacteria
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
CN101022826A (zh) * 2004-06-07 2007-08-22 哈罗尔·戴维·贡 用于癌症治疗的细菌组合物
US8034359B2 (en) * 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
WO2008049231A1 (en) * 2006-10-27 2008-05-02 Harold David Gunn Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CA2576280A1 (en) * 2004-08-13 2006-02-16 Barry J. Marshall Helicobacter pylori-based delivery system
US8029777B2 (en) * 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8092793B2 (en) 2004-12-15 2012-01-10 Qingdao East Sea Pharmaceuticals, Ltd. Treating inflammatory bowel disease with live bacteria
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
WO2007076534A1 (en) 2005-12-29 2007-07-05 Hill's Pet Nutrition, Inc. Method for modifying gut flora in animals
US20090252708A1 (en) 2006-05-18 2009-10-08 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
CA2662101C (en) * 2006-08-28 2015-07-07 Omnio Healer Ab Candidates against infection
CA2997459C (en) * 2006-10-27 2020-09-22 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
CN101085347B (zh) * 2007-06-15 2010-05-19 东南大学 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗
MX2010000864A (es) * 2007-07-23 2010-04-30 Vaccine Res Internat Plc Vacuna de celulas enteras estafilococcicas inactivadas.
EP2188366A1 (en) 2007-08-16 2010-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Human specific escherichia coli strains
US20110027348A1 (en) * 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
WO2010068413A1 (en) * 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides
ES2778836T3 (es) 2009-03-05 2020-08-12 Probiotical Spa Cepas de bacterias que tienen una alta actividad antiinflamatoria
PL2598165T3 (pl) 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
JP6012071B2 (ja) 2012-12-03 2016-10-25 太平洋セメント株式会社 塩素バイパス排ガスの処理方法

Also Published As

Publication number Publication date
AU2021203627B2 (en) 2024-11-14
JP5923501B2 (ja) 2016-05-24
US20120258135A1 (en) 2012-10-11
CA3255684A1 (en) 2025-05-23
RU2722357C2 (ru) 2020-05-29
CN103140238A (zh) 2013-06-05
JP2013532665A (ja) 2013-08-19
SG187201A1 (en) 2013-02-28
EP2598165A4 (en) 2014-03-26
EP4324526A3 (en) 2024-05-22
RU2581922C2 (ru) 2016-04-20
CN105797145A (zh) 2016-07-27
CN103140238B (zh) 2016-03-16
AU2011284737A8 (en) 2016-08-04
AU2011284737B2 (en) 2016-07-07
IL277110B (en) 2022-10-01
IL277110A (en) 2020-10-29
KR20180115354A (ko) 2018-10-22
JP2017149751A (ja) 2017-08-31
WO2012012874A1 (en) 2012-02-02
KR101916853B1 (ko) 2018-11-09
NZ606490A (en) 2015-04-24
AU2016238866B2 (en) 2018-07-19
JP2019070040A (ja) 2019-05-09
KR20130132762A (ko) 2013-12-05
EP2598165B1 (en) 2017-09-20
SG10201604175XA (en) 2016-07-28
AU2021203627A1 (en) 2021-07-01
RU2016106134A3 (pl) 2019-07-17
JP6129378B2 (ja) 2017-05-17
ES2971415T3 (es) 2024-06-05
US10130692B2 (en) 2018-11-20
ES2645509T3 (es) 2017-12-05
KR102157718B1 (ko) 2020-09-18
AU2018250480A1 (en) 2018-11-15
CA2804709A1 (en) 2012-02-02
RU2013108248A (ru) 2014-09-10
AU2011284737A1 (en) 2013-02-28
EP2598165A1 (en) 2013-06-05
EP3235506B1 (en) 2023-12-06
JP2021088568A (ja) 2021-06-10
IL224048B (en) 2020-09-30
EP3235506A1 (en) 2017-10-25
JP2016193902A (ja) 2016-11-17
AU2016238866A1 (en) 2016-10-27
AU2018250480B2 (en) 2021-03-04
NZ702796A (en) 2017-03-31
EP3235506C0 (en) 2023-12-06
DK2598165T3 (en) 2017-10-16
IL277110B2 (en) 2023-02-01
MX2013001032A (es) 2013-06-05
MY188328A (en) 2021-11-30
JP6471188B2 (ja) 2019-02-13
MX345240B (es) 2017-01-23
EP4324526A2 (en) 2024-02-21
RU2016106134A (ru) 2018-11-22

Similar Documents

Publication Publication Date Title
IL277110A (en) Immunogenic anti-inflammatory preparations
SMT201600350B (it) Composizioni farmaceutiche
DK2640893T4 (da) Sammensætninger
LT3246021T (lt) Apiksabano kompozicijos
BR112012031667A2 (pt) composição
BR112012032683A2 (pt) composição
SMT201700110B (it) Composizione immunogena
EP2552472A4 (en) INFLAMMATION INHIBITING FACTORS
EP2636704A4 (en) FILM FORMING COMPOSITION
BRPI1005919A2 (pt) composição imunogênica
EP2515938A4 (en) IMMUNOGENIC COMPOSITIONS
BR112012032980A2 (pt) composição
EP2628769A4 (en) FILM FORMING COMPOSITION
BR112013014612A2 (pt) composições moc
EP2635269A4 (en) COMBINATION COMPOSITION
CO6801722A2 (es) Composiciones farmacéuticas
EP2624836A4 (en) BEPOTASTIN COMPOSITION
EP2609931A4 (en) IMMUNOGENIC COMPOSITION
SMT201200040B (it) Composizioni di flupentixol
BR112013031545A2 (pt) composições cosméticas
PT2397136T (pt) Composição anti-inflamatória
BR112013014673A2 (pt) composições orais
BR112013000109A2 (pt) composições
EP2575743A4 (en) WELD-INHIBITING COMPOSITIONS
DK2646506T3 (da) Tiksotrope sammensætninger